Assignee
OGEDA SA
BE19 patents
Top patents by PatentIndex Score
US10836768B2Nov 17, 2020
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA1 citations72
US10787458B2Sep 29, 2020
Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines
OGEDA SA2 citations72
US10183948B2Jan 22, 2019
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA1 citations72
US9987274B2Jun 5, 2018
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA4 citations72
US9969745B2May 15, 2018
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
OGEDA SA2 citations72
US11478472B2Oct 25, 2022
NK-3 receptor antagonists for therapeutic treatment of leptin-related disease
OGEDA SA1 citations71
US10624890B2Apr 21, 2020
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
OGEDA SA2 citations71
US10683295B2Jun 16, 2020
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
OGEDA SA1 citations67
US12162849B2Dec 10, 2024
Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof
OGEDA SA0 citations62
US11731974B2Aug 22, 2023
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA0 citations62
US11078203B2Aug 3, 2021
Deuterated fezolinetant
OGEDA SA1 citations62
US12458641B2Nov 4, 2025
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
OGEDA SA0 citations61
US10941151B2Mar 9, 2021
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
OGEDA SA0 citations58
US10214533B2Feb 26, 2019
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
OGEDA SA0 citations51
US9926325B2Mar 27, 2018
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
OGEDA SA0 citations51
US10544150B2Jan 28, 2020
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
OGEDA SA0 citations49
US10358416B2Jul 23, 2019
Substituted pyrrolidines as G-protein coupled receptor 43 agonists
OGEDA SA0 citations48
US10017468B2Jul 10, 2018
Substituted pyrrolidines as G-protein coupled receptor 43 agonists
OGEDA SA0 citations48
US10065960B2Sep 4, 2018
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
OGEDA SA0 citations40